A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy
NCT06476899 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2024-06-27
Summary
Prospective, interventional, and practical clinical studies
Conditions
- CLL/SLL
Interventions
- DRUG
-
orelabrutinib
orelabrutinib tablets
- DRUG
-
FCR/BR
FCR/BR
- DRUG
-
BTK inhibitor
BTK inhibitor choose by physican
Sponsors & Collaborators
-
Fei Li
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-07-24
- Primary Completion
- 2026-03-26
- Completion
- 2026-12-26
More Related Trials
-
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
NCT06466122 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
NCT06524375 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
NCT05322733 ·Status: RECRUITING ·Phase: PHASE2
-
the Efficacy and Safety of CLAE in R/R T-ALL/LBL
NCT04679506 ·Status: UNKNOWN
-
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
NCT02639910 ·Status: COMPLETED ·Phase: PHASE2
-
The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China
NCT06557304 ·Status: NOT_YET_RECRUITING
-
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
NCT06651970 ·Status: RECRUITING ·Phase: PHASE4
-
A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib
NCT05491044 ·Status: RECRUITING ·Phase: PHASE2
-
Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL
NCT01722487 ·Status: COMPLETED ·Phase: PHASE3
-
Mosunetuzumab for CLL MRD Clearance
NCT07052695 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT06520098 ·Status: RECRUITING ·Phase: PHASE2
-
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT02556346 ·Status: WITHDRAWN ·Phase: PHASE1
-
STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT04963946 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT01243190 ·Status: COMPLETED ·Phase: PHASE2
-
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
NCT00536341 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
NCT06978088 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
NCT00751296 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT03206918 ·Status: COMPLETED ·Phase: PHASE2
-
MEOI and HRQoL in CLL Patients Treated With BTKis
NCT04938141 ·Status: COMPLETED
-
A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom
NCT05555979 ·Status: COMPLETED
-
A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06839872 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
NCT06697184 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
NCT01183663 ·Status: COMPLETED ·Phase: PHASE1
-
Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
NCT06812715 ·Status: RECRUITING ·Phase: PHASE2
-
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
NCT04608318 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3